My Cancer Genome: Genetically Informed Cancer Medicine

  • Home
  • DIRECT
  • About Us
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Anaplastic Large Cell Lymphoma
  • Basal Cell Carcinoma
  • Bladder Cancer
  • Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Colorectal Cancer
  • GIST
  • Gastric Cancer
  • Glioma
  • Inflammatory Myofibroblastic Tumor
  • Lung Cancer
  • Medulloblastoma
  • Melanoma
  • Myelodysplastic Syndromes
  • Neuroblastoma
  • Ovarian Cancer
  • Prostate Cancer
  • Rhabdomyosarcoma
  • Thymic Carcinoma
  • Thyroid Cancer
  • Molecular Medicine
    • Anticancer Agents
    • Circulating Tumor DNA
    • Detecting Gene Alterations in Cancers
    • Immunotherapy in Cancer
    • Overview of Targeted Therapies for Cancer
    • Pathways
    • Types of Molecular Tumor Testing
  • Take Our Survey
  • Glossary
  • News
  • Our Team
  • Acknowledgements

Cell Cycle Control

The cell cycle involves regulated cell growth, replication, and division. The cell cycle includes four distinct phases: G1 (gap phase 1), S (DNA synthesis), G2 (gap phase 2), and M (mitosis). Cell cycle regulation (both activation and inhibition) is dependent upon specific cell cycle checkpoints, which prevent abnormal cell cycle activation and continuation. For example, the G2/M checkpoint ensures that cells containing damaged DNA do not enter mitosis. These cell cycle checkpoints are controlled by the coordinated action of CDK+cyclin binding pairs including CDK4/6+cyclin D, RB1/E2F, CDK2+cyclin E, CDK2+cyclin A, CDK1+cyclin A, CDK1+cyclin B.

Cell Cycle Control

Figure 1. The cell cycle is a set of processes through which a cell divides to become two identical daughter cells. The cell cycle encompasses four phases including G1 (gap phase 1), S (DNA synthesis), G2 (gap phase 2), and M (mitosis). The cell cycle is controlled by the complex interplay of cyclin-dependent kinases (CDK -1, -2, -4, -6, -8, -12) and cyclins (cyclin -A, -B, -D, -E). Heterodimers of cyclins and CDKs function at different points in the cycle. There are several checks and balances, called checkpoints, in the cell cycle to ensure integrity of daughter cells. Checkpoints include the G1/S checkpoint and the G2/M checkpoint. Of particular relevance, p21 and p27 function as regulators of the G1 and S checkpoints. These checkpoints become important in the setting of DNA damage. DNA damage activates these checkpoints to ensure genomic integrity by repairing damaged DNA or forcing the cell to enter a programmed cell death pathway if DNA cannot be repaired. Checkpoints and DNA damage responses are altered in numerous malignancies. Specific nodes in the pathway that are therapeutically actionable are noted. Click here to open a larger version of this image in a new window.

Upstream Pathways

  • JAK/STAT signaling
  • Kinase fusions
  • MAP kinase signaling
  • PI3K/AKT1/MTOR signaling
  • Receptor tyrosine kinase/growth factor signaling

Diseases in Which Pathway is Aberrantly Activated

  • Acute myeloid leukemia
  • Bladder cancer
  • Breast cancer
  • Myelodysplastic syndromes

Therapies That Target This Pathway

  • CDK inhibitors
  • CDK1 inhibitors
  • CDK2 inhibitors
  • CDK4/6 inhibitors

Genes Involved in the Pathway

  • AURKA
  • AURKB
  • CCND1
  • CCND2
  • CCND3
  • CDK1
  • CDK2
  • CDK3
  • CDK4
  • CDK6
  • CDK8
  • CDK12
  • CDKN1B
  • CDKN2A
  • CDKN2B
  • CDKN2C
  • CHEK1
  • CHEK2
  • CCNA1
  • CCNA2
  • CCNB1
  • CCNB2
  • CCNB3
  • CCNE1
  • CCNE2
  • E2F1
  • C11orf30 (EMSY)
  • RB1
  • TP53

Last Updated: July 1, 2016

Disclaimer: The information presented at MyCancerGenome.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.

  • MCG Home |
  • About Us |
  • Acknowledgments |
  • Give |
  • Site Map |
  • Legal |
  • APIs and Licensing
My Cancer Genome is managed by the Vanderbilt-Ingram Cancer Center   Copyright © 2010 - 2017 MY CANCER GENOME